CMT Research Foundation is pleased to announce that Dr. Yulia Grishchuk, Ph.D., has joined the Foundation’s Scientific Advisory Board.
The SAB is composed of distinguished scientific and clinical experts specializing in Charcot-Marie-Tooth disease and drug development. The SAB plays a vital role in the Foundation’s mission by evaluating and selecting research projects with the highest scientific merit for funding, ensuring impactful investments in research that advances and accelerates the development of treatments and cures for CMT. In nearly seven years, CMTRF has become a significant force in the CMT research arena, funding nearly 30 research projects, with five now in preclinical or active trials.
In addition to joining CMTRF’s SAB, Dr. Grishchuk currently works as an associate director of regulatory affairs at the Gene and Cell Therapy Institute, Mass General Brigham. Previously, she was an assistant professor of neurology at Harvard Medical School and principal investigator at the Center for Genomic Medicine at Massachusetts General Hospital.
Dr. Grishchuk’s expertise lies in lysosomal biology, autophagy and preclinical development of gene and cell therapies, with a focus on translating scientific discoveries into clinical interventions. Her work has led to promising gene therapy strategies and biomarker development for disorders such as mucolipidosis IV, beta-propeller protein-associated neurodegeneration and other lysosomal diseases.
“I am deeply passionate about integrating scientific breakthroughs with translational development, biomarker discovery and regulatory science to bring new hope to patients with rare CNS disorders,” said Dr. Grishchuk. “I strongly believe in the power of collaboration between families, foundations and researchers to drive meaningful progress for those living with rare conditions, and I am looking forward to being a part of the Scientific Advisory Board at CMTRF.”
Dr. Grishchuk is also a member of the Patient Outreach Committee at the American Society of Gene and Cell Therapy.
“We are thrilled to welcome Dr. Yulia Grishchuk to the Foundation’s Scientific Advisory Board,” said Laura M. MacNeill, CEO of the CMT Research Foundation. “As we look ahead to projects in need of funding, we hope to leverage her insights and expertise from other disease types to help guide us toward the greatest possible impact for families living with this disease.”
Dr. Grishchuk received her Ph.D. in molecular biology from the Engelhardt Institute of Molecular Biology in Moscow, Russia.